GeneTether Therapeutics Inc.’s C$4.5 Million Initial Public Offering

Fasken Martineau DuMoulin LLP advised Research Capital Corporation on the matter. GeneTether Therapeutics Inc. (CSE: GTTX), an innovative genetic medicines company, completed an initial public offering of…

This content is for Standard 1 Year members only.
Login Join Now
Sonia Carcano

Author: Sonia Carcano

This content is for Standard 1 Year members only.
Login Join Now